Table 2 Clinical and treatment characteristics in the SUVmax-M-low and SUVmax-M-high group
|  | SUVmax-M < 10 | SUVmax-M ≥ 10 | P value |
|---|---|---|---|
|  | N = 51, % | N = 35, % |  |
Age | 47.2 ± 11.4 | 44.3 ± 11.4 | 0.245 |
Gender | Â | Â | 0.518 |
 Male | 7 (13.7%) | 3 (8.57%) |  |
 Female | 44 (86.3%) | 32 (91.4%) |  |
T stage | Â | Â | 0.568 |
 T1-2 | 22 (44.0%) | 12 (35.3%) |  |
 T3-4 | 28 (56.0%) | 22 (64.7%) |  |
N stage | Â | Â | 0.733 |
 N0-1 | 7 (14.0%) | 3 (8.82%) |  |
 N2-3 | 43 (86.0%) | 31 (91.2%) |  |
Metastatic sites | 3.51 (2.71) | 4.71 (3.12) | 0.068 |
Presence of liver | Â | Â | 1 |
 No | 38 (74.5%) | 26 (74.3%) |  |
 Yes | 13 (25.5%) | 9 (25.7%) |  |
Metastatic organs | Â | Â | 0.437 |
 Single | 40 (78.4%) | 24 (68.6%) |  |
 Multiple | 11 (21.6%) | 11 (31.4%) |  |
SUVmax-T | 10.8 ± 4.18 | 12.9 ± 5.56 | 0.061 |
SUVmax-N | 9.76 ± 5.04 | 13.7 ± 5.57 | 0.001 |
Serum LDH | 242 ± 99.8 | 469 ± 773 | 0.092 |
ACT | Â | Â | 0.513 |
 No | 43 (84.3%) | 32 (91.4%) |  |
 Yes | 8 (15.7%) | 3 (8.57%) |  |
CCRT | Â | Â | 0.577 |
 No | 43 (84.3%) | 27 (77.1%) |  |
 Yes | 8 (15.7%) | 8 (22.9%) |  |
IC circles | 5.53 ± 0.97 | 5.51 ± 1.58 | 0.960 |